



三生制药
3SBIO INC.

(Incorporated in the Cayman Islands with limited liability)
(於開曼群島註冊成立的有限責任公司)
(Stock Code 股份代號: 1530)

NOTIFICATION LETTER 通知信函

28 April 2023

Dear Shareholders / Non-Registered Shareholders,

3SBIO INC. (the “Company”)

— Notice of Publication of Environmental, Social and Governance Report for year 2022 (“Current ESG report”)

The English and Chinese versions of the Company’s Current ESG report are available on the Company’s website at www.3sbio.com and the HKExnews’s website at www.hkexnews.hk. You may access the Current ESG report by clicking “Investor” at the top of the home page of our website, then in the middle of the “Investor” page clicking “Reports Download”, then on “Reports Download” page selecting “ESG Reports” and “2022 Environmental, Social and Governance Report” and viewing it using Adobe® Reader®; or browsing through the HKExnews’s website.

If shareholders have difficulty in gaining access to the Current ESG report posted on the Company’s website and you want to request printed version(s) of the ESG report, please send a letter stating your request with signature by mail to the Company’s Hong Kong Share Registrar. The address of the Hong Kong Share Registrar is 17M Floor, Hopewell Centre, 183 Queen’s Road East, Wanchai, Hong Kong.

By Order of the Board
3SBio Inc.
Dr. LOU Jing
Chairman

(1) This letter is addressed to shareholders and non-registered shareholders (“Non-registered shareholder” means such person or company whose shares are held in The Central Clearing and Settlement System (CCASS)). If you have sold or transferred your Shares of the Company, please disregard this notification letter.

各位股份持有人 / 非登記股份持有人：

三生制藥（「本公司」）

— 2022 年度環境、社會及管治報告之發佈通知（「本次 ESG 報告」）

本公司的本次 ESG 報告中，英文版本已上載於本公司網站 www.3sbio.com 及香港交易所披露易網站 www.hkexnews.hk，歡迎瀏覽。閣下可於本公司網站主頁頂部點擊「投資者」一項，再在「投資者」頁面中部點擊「相關報告下載」，進入「相關報告下載」頁面後選擇「ESG 報告」項及「2022 年度環境、社會及管治報告」並使用 Adobe® Reader 開啟，或在香港交易所披露易網站瀏覽獲取該檔。

倘閣下於存取本公司網站上的本次 ESG 報告出現困難及欲要求索取本次 ESG 報告之印刷本，請寄回已簽署書面要求至香港證券登記處。香港證券登記處地址為香港灣仔皇后大道東 183 號合和中心 17M 樓。

承董事會命
三生制藥
董事長
婁競博士

2023 年 4 月 28 日

(1) 此函件乃向本公司之股份持有人及非登記股份持有人（「非登記股份持有人」指其股份存放於中央結算及交收系統的人士或公司）而發出。如果閣下已經出售或轉讓本公司的股票，請毋須理會本通知信函。